Related Experiment Videos
Controlled trials and chemoprevention of cancer
1Department of Public Health, University of Helsinki, Finland.
Abstract:
Epidemiological and laboratory studies provide preliminary evidence that a compound may prevent certain types of clinical cancer. The final proof for practical application demands two controlled trials with similar, decisive results. Controlled chemoprevention trials on clinical cancer are large, time-consuming and expensive, whereas studies on cancer surrogates are smaller but less reliable. Rational trial design often lacks sufficient information about the sensitive period and the time from that point to clinically detectable cancer. The correct dose of chemopreventive agent and an expected preventive fraction of cancer are also often based on informed guesswork. Long trials call for special arrangements to guarantee the staying will of the participants and key research personnel. Although large chemoprevention trials are currently being carried out without any certainty of successful outcome, the situation is not so different from the early days of chemoprevention trials for cardiovascular diseases. Cancer trials will be conducted based on the 'learning-by-doing' approach, and in the more distant future based on research designed to provide information for trial needs.
Insights
Preliminary evidence suggests a compound may prevent cancer, but definitive proof requires large, controlled trials. Designing these cancer prevention studies involves challenges in participant retention and dose determination, often using a learning-by-doing approach.
Area of Science:
- Oncology
- Preventive Medicine
- Clinical Trials
Background:
- Epidemiological and laboratory studies suggest a compound's potential for cancer prevention.
- Definitive proof requires large, controlled clinical trials, which are resource-intensive and lengthy.
- Current trial designs often lack precise data on sensitive periods and cancer development timelines.
Purpose of the Study:
- To discuss the challenges and considerations in designing and conducting controlled chemoprevention trials for clinical cancer.
- To highlight the need for robust evidence beyond preliminary findings.
- To explore strategies for overcoming logistical and informational hurdles in cancer prevention research.
Main Methods:
- Review of existing evidence and methodologies in chemoprevention research.
- Analysis of the requirements for definitive clinical cancer prevention trials.
- Discussion of the 'learning-by-doing' approach in trial design.
Main Results:
- Controlled clinical cancer trials are essential but pose significant challenges in terms of size, duration, and cost.
- Studies using cancer surrogates are less reliable but smaller and quicker.
- Accurate determination of chemopreventive agent dosage and expected cancer prevention fraction remains difficult.
Conclusions:
- Large-scale, controlled chemoprevention trials are necessary for validating cancer-preventive compounds.
- Effective trial design requires addressing participant retention and optimizing the use of preliminary data.
- Future research should focus on generating data to inform more precise trial designs, moving beyond the 'learning-by-doing' approach.